AnaptysBio (AN6) Stock Overview
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AN6 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.86 |
| 52 Week High | US$60.58 |
| 52 Week Low | US$16.00 |
| Beta | 0.41 |
| 1 Month Change | 10.59% |
| 3 Month Change | 32.81% |
| 1 Year Change | 171.08% |
| 3 Year Change | 175.31% |
| 5 Year Change | 151.71% |
| Change since IPO | -2.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| AN6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.4% | 2.6% | -2.1% |
| 1Y | 171.1% | -4.7% | 1.7% |
Return vs Industry: AN6 exceeded the German Biotechs industry which returned -8.1% over the past year.
Return vs Market: AN6 exceeded the German Market which returned 2.6% over the past year.
Price Volatility
| AN6 volatility | |
|---|---|
| AN6 Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: AN6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AN6's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 104 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| AN6 fundamental statistics | |
|---|---|
| Market cap | €1.63b |
| Earnings (TTM) | -€11.33m |
| Revenue (TTM) | €200.94m |
Is AN6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AN6 income statement (TTM) | |
|---|---|
| Revenue | US$234.60m |
| Cost of Revenue | US$135.97m |
| Gross Profit | US$98.63m |
| Other Expenses | US$111.87m |
| Earnings | -US$13.23m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 42.04% |
| Net Profit Margin | -5.64% |
| Debt/Equity Ratio | 743.2% |
How did AN6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/29 03:58 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AnaptysBio, Inc. is covered by 21 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Etzer Darout | Barclays |
| Michael King | Citizens JMP Securities, LLC |